Across TCGA pan-cancer cohorts, GBP7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GBP7 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GBP7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GBP7 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where GBP7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.875	0.498	.001	16	view →
PDAC	OS	Median	III,IV	0.402	0.898	.008	6	view →
LUAD	OS	Median	All	0.917	0.999	.010	5	view →
LSCC	DFS	Median	III,IV	0.979	0.567	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: GBP7 tumor-vs-normal RNA expression · all GBP7 data types